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Background: Fractional exhaled nitric oxide (FeNO) is amarker of type-2 inflammation used both to
supportdiagnosisof asthmaand followupasthmapatients.Theassociationsof FeNOwith lung function
decline and bronchodilator (BD) response have been studied only scarcely in large populations.
Objectives: To study the association between FeNO and a) retrospective lung function decline
over 20 years, and b) lung function response to BD among asthmatic subjects compared with non-
asthmatic subjects and with regards to current smoking and sex.
Methods: Longitudinal analyses of previous lung function decline and FeNO level at follow-up
and cross-sectional analyses of BD response and FeNO levels in 4257 participants (651 asth-
matics) from the European Community Respiratory Health Survey.
Results: Among asthmatic subjects, higher percentage declines of FEV1 and FEV1/FVC were asso-
ciatedwithhigherFeNOlevels (p¼0.001 forboth)at follow-up.Thesecorrelationswere foundmainly
among non-smoking individuals (p¼ 0.001) and females (p¼ 0.001) in stratified analyses.
Percentage increase in FEV1 after BD was positively associated with FeNO levels in non-asthmatic
subjects. Further, after stratified for sex and smoking separately, a positive association was seen
between FEV1 and FeNO levels in non-smokers and women, regardless of asthma status.
Conclusions: We found a relationship between elevated FeNO and larger FEV1 decline over 20
years among subjects with asthma who were non-smokers or women. The association between
elevated FeNO levels and larger BD response was found in both non-asthmatic and asthmatic
subjects, mainly in women and non-smoking subjects.
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http://doi.org/10.1016/j.waojou.2021.100544INTRODUCTION response in subjects with asthma has beenFractional exhaled nitric oxide (FeNO) is based
on a non-invasive method to measure nitric oxide
(NO) in exhaled air and is a biomarker of type-2
inflammation,1 reflecting activation of IL-4/-13-
driven mechanisms.2 Increased FeNO is related
to response to inhaled corticosteroids in both
subjects with asthma3 and subjects with
nonspecific respiratory airway symptoms.4 FeNO
has a clinical role in the diagnostic workup of
asthma and the monitoring of patients with
asthma.5
Lung function is often assessed by measuring
forced expiratory volume in 1 sec (FEV1) and
forced vital capacity (FVC). Early identification of
subjects at risk of accelerated decline in lung
function is important, as irreversible airflow
obstruction is known to be associated with
increased morbidity and mortality.6 Lung function
decline is faster in asthmatics than in healthy
subjects.7,8 Factors contributing to accelerated
lung function decline in patients with asthma are
smoking,7 recurrent exacerbations,9 and low
baseline FEV1.
10 Evidence suggests that airway
inflammation may play an important role in the
progression of lung function impairment in
asthma.11,12 Eosinophil inflammation appears to
relate to accelerated lung function decline13 in
both asthmatic and non-asthmatic individuals.
However, FeNO has been studied only scarcely in
relation to lung function decline. Evidence from
small, selected populations of asthmatics suggests
that higher FeNO levels predict larger lung func-
tion decline.14–16 To our knowledge, no studies
have investigated the relation between FeNO
levels and lung function decline in population-
based surveys.
The relation between FeNO and bronchial
hyperresponsiveness to indirect stimuli, such as
exercise or mannitol, is moderate.17,18 In lung
function testing, asthma patients show a larger
significant bronchodilator (BD) response in
lung function to a greater extent than those
without asthma,19 and the BD test is used in
the diagnostic workup of asthma (Global
Initiative for Asthma, https://ginasthma.org). An
association between increased FeNO and BDfound in two population-based studies.19
FeNO values are influenced by a number of
factors, for example age,20 sex,20,21 height,20
atopy,20,21 smoking,20,22 respiratory infections,20
and environmental factors.23 One of the most
important factors in terms of magnitude is
cigarette smoking, with a mean reduction of
FeNO by up to 50%, depending on the extent of
cigarette consumption.24 Sex is another
important factor, with females consistently
reporting about 25% lower FeNO levels than
men.20,21 However, sex differences are seldom
accounted for in studies on FeNO, and smoking
status is usually only adjusted for.
Our primary aim was to study if previous lung
function decline was related to FeNO in a long-
term follow-up of a population-based adult
cohort and whether it differed between asth-
matic and non-asthmatic subjects. Our second-
ary aim was to study the association between
lung function response to BD and FeNO with
regard to presence of asthma. Lastly, we aimed
to study all these associations in relation to
current smoking status and sex.
METHODS
Study sample
This is a prospective study based on the first
and third surveys in the European Community
Respiratory Health Survey (ECRHS I and III),
performed during the periods 1990–1994 and
2010–2013, respectively, using data from 23
centres across 10 European countries and
Australia.
Briefly, ECRHS is an international multicentre
population-based study with the aim to determine
the prevalence of and risk factors for the devel-
opment of asthma, allergic disease, atopy, and
rapid loss of lung function in middle-aged adults
living in Europe and Australia. ECRHS I was first
performed in the early 1990s, in subjects aged 20–
44 years. The subjects were randomly selected to
complete a short postal questionnaire about
asthma symptoms and attacks in the preceding 12
months, current use of asthma medication, and
presence of nasal allergies, including hay fever.
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of responders were then invited to attend further
examinations at their study centre.
In ECRHS III, subjects who participated in the
clinical part of ECRHS I were sent a short postal
questionnaire. Those who responded were invited
to participate in lung function and blood tests and
to fill out additional questionnaires. Further details
about ECRHS have been published elsewhere25,26
and can also be found on its website: www.ecrhs.
org.
The current analyses were restricted to 5295
adults from the full cohort (random and symp-
tomatic sample) who participated in both surveys
(ECRHS I and ECRHS III) and had valid information
on FeNO from ECRHS III. We excluded 956 sub-
jects with missing values (asthma and FEV1) and 82Fig. 1 Flowchart showing the selection process and numbers of subjec
(BD) are specified in the methods section. ECRHS, European Communsubjects with a diagnosis of chronic obstructive
pulmonary disease (COPD) or emphysema,
resulting in 4257 subjects. Of these, 651 had self-
reported asthma. For analysis of bronchodilation,
we had a total of 4073 subjects with both pre- and
post-FEV1 data, Fig. 1.Questionnaires
The participants were asked in an interviewer-
led questionnaire whether they had respiratory
symptoms, asthma, or COPD, and about their
smoking habits and use of inhaled corticosteroids
in the preceding 12 months. They were also asked
whether they had any nasal allergies, including hay
fever.
The asthma group consisted of participants with
current asthma. Current asthma was defined asts available for analyses. Definitions of asthma and bronchodilator
ity Respiratory Health Survey. FeNO, fractional exhaled nitric oxide
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1 asthma-related symptom (wheeze, nocturnal
chest tightness or attacks of breathlessness
following activity, at rest or at night) and/or re-
ported current use of inhaled corticosteroids dur-
ing the last 12 months. Asthma duration was
defined as age at the clinical visit minus the self-
reported age of asthma diagnosis. Chronic sinus-
itis with nasal polyposis were defined as self-
reported doctor’s diagnosis of the respective
conditions.
The non-asthma group consisted of subjects
that did not fulfil the criteria for current asthma.
COPD and emphysema were defined as a self-
reported physician’s diagnosis. Use of inhaled
corticosteroids was defined in 2 ways: “ever used
inhaled medicine to help breathing at any time in
the last 12 months” and “used inhaled steroids
(only) in the last 12 months” or “used inhaled
medicine to help breathing at any time in the last
12 months” and “frequent inhaled steroid use in
the last 3 months”. Oral steroid intake was defined
as “used oral medicine to help breathing at any
time in the last 12 months and used oral steroid
tablets in the last 3 months”.Measurements of FeNO
FeNO measurements (only available from
ECHRS III) were performed in accordance with the
recommendations of the American Thoracic Soci-
ety,27 with the exception that they were performed
as single measurements28 by using hand-held
portable sampling devices (NIOX MINO Aero-
crine AB, Solna, Sweden). Patients were instructed
to avoid smoking, eating, drinking, and strenuous
exercise for at least 1 h before the test.
Values below 5 ppb (the lower limit of detection
of the device) were recorded in 20 subjects and
these individuals were given an arbitrary value of
3.5 ppb (5 divided by O2).Lung function
Spirometry was performed at both baseline and
follow-up, but bronchodilation test was only per-
formed in ECRHS III. Spirometry was performed
using an EasyOne spirometer (ndd Medical Tech-
nologies Inc., Andover, MA, USA) in ECRHS III, but
a Biomedin spirometer was used (Biomedin srl,Padua, Italy) in ECRHS I. Some centres had other
equipment, but these differences are not believed
to have affected the homogeneity of the results.29
The type of spirometer used at each centre has
been presented by Accordini et al.30
Spirometry measurements were performed with
the study person in a sitting position, wearing a
nose clip, and in accordance with the instructions
of the American Thoracic Society (ATS)/European
Respiratory Society (ERS).31 All spirometry tests
fulfilled the ATS data collection standards
regarding validity of measurements, ie, 5 or more
acceptable spirometry performances.
Variables obtained from spirometry and used in
this study included FEV1, FVC, and FEV1/FVC ratio.
Lung function changes (% change/year [D]) have
been calculated with regards to DFEV1, DFVC, and
DFEV1/FVC ratio. The calculation was performed as
100*(value at ECRHS I - value at ECRHS III)/value at
ECRHS I divided by the actual time between the
baseline and follow-up, ie, a positive value repre-
sented decline.
In ECRHS III, spirometry was performed before
and after 15 min after bronchodilation with 200
mcg salbutamol via a metred dose inhaler with a
Volumatic spacer.
Reversibility in FEV1 was expressed as % change
and calculated as follows: (the difference between
pre- and post-bronchodilator FEV1 divided by pre-
bronchodilator FEV1) *100.
Anthropometry
Participants’ height and weight were measured
by trained health technicians and used to calculate
body mass index (BMI) (weight [kg]/height [m2]).
Immunoglobulin E measurements
Allergen-specific immunoglobulin E (IgE) was
measured against house dust mite, cat, and
timothy grass. Analysis was performed in a single
central laboratory (AMC Amsterdam) using the
ImmunoCAP system (Thermo Fisher Scientific,
Uppsala, Sweden). The assay was calibrated
against the WHO standard for IgE with a range of
0.35–100 kU/l. A positive IgE was defined as  0.35
kU/l for one or more of house dust mite, cat, and
timothy grass. In this study, data on IgE sensitisa-
tion were available only from 3542 subjects.
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A current smoker was defined as someone who
had smoked at least 20 packets of cigarettes or
360 g of tobacco in his/here life time (which equals
at least 1 cigarette a day or 1 cigar a week for at
least a year) and was still smoking during the
month preceding the study. Non-smokers were
subjects who answered questions on smoking
habits and were not fulfilling the criteria for current
smoker.Statistical methods
All analyses were performed using StataSE 15.1
(StataCorp, College Station, TX, USA). The results
were summarised as arithmetic and geometric
means and b coefficients with 95% confidence in-
tervals (95% CI). Logarithmic transformation was
performed for variables with right-skewed distri-
bution (FeNO). FeNO level is described using
geometric means and lung function response to
BD is described using arithmetic means. Differ-
ences between groups were compared using
Student’s t-test.
We modelled the longitudinal impact of
changes in lung function between ECRHS I to III on
FeNO level (outcome) at ECRHS III. The cohort was
divided into 2 groups: subjects free from asthma
and subjects with asthma. Multiple linear regres-
sion analyses were stratified by sex and smoking
status (2 strata: non and current smokers), adjusted
for sex, age, height, atopy, inhaled steroids,
smoking status, and study centre at follow-up
(ECRHS III).
The interactions between sex and lung function
(% change/year) between ECRHS I and ECRHS III
with regards to FEV1, FVC, and FEV1/FVC ratio
and, in ECHRS III, FEV1, FVC, and FEV1/FVC ratio,
with BD) on FeNO were evaluated, adjusted for
sex, age, height, atopy, inhaled steroids, smoking
status, and study centre.
Multiple linear regression analyses were used to
assess cross-sectional associations between lung
function response to BD (expressed as % change)
and FeNO level (outcome) in non-asthma/asthma
subjects. Both groups were also stratified sepa-
rately by smoking status (two strata: non andcurrent smokers) and sex. All analyses were
adjusted for sex, age, height, smoking, atopy,
inhaled steroids, oral steroids, and study centre.
A p value of <0.05 was considered statistically
significant.
Ethics
Informed consent was obtained from all partic-
ipants prior to inclusion in ECRHS I and III. Each
study centre obtained approval for the study from
their regional committee of medical research
ethics in accordance with national legislation.RESULTS
In ECRHS III, 2031 (47.7%) of the 4257 par-
ticipants were men and 651 subjects had self-
reported asthma. The mean age was 54.1
(7.1) years. Exhaled NO levels were higher in
asthmatic than non-asthmatic subjects: (geo-
metric mean) 21.1 vs. 16.5 ppb, p < 0.001.
When stratified by asthma and smoking status,
non-smokers were seen to have higher FeNO
levels than smokers: 23.4 vs 11.9 ppb. When
stratified by sex, men were seen to have higher
FeNO levels than women, regardless of asthma
status, see Table 1.
Change in lung function over time and in relation
to asthma status
Non-asthmatic subjects had lower % change
per year [D] of FEV1 compared with asthmatic
subjects. The same pattern was seen between
non-smokers/smokers regardless of whether or
not they had asthma. Men and women with
asthma had higher DFEV1 than non-asthmatic
subjects.
Women with non-asthma seemed to have
higher DFEV1 and DFEV1/FVC ratio than men. In
asthmatic subjects, women had higher % change
in DFEV1/FVC ratio compared with men, see
Table 2.
Change in lung function over time and in relation
to FeNO levels
In subjects with asthma, a greater decline in
DFEV1 and DFEV1/FVC ratio were associated
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age, height, weight, atopy, inhaled steroids,
smoking status, and study centre, p < 0.001 forVariable
Sex (men), n (%)
Age (years)







ECHRS I / ECHRS III % decline/year
FVC (litre)
FVC (% predicted)
ECHRS I / ECHRS III % decline/year
FEV1/FVC
ECHRS I / ECHRS III % decline/year
FEV1 post BD (litre), n ¼ 3440/633
FVC post BD (litre), n ¼ 3406/621
FEV1/FVC-post BD %, n ¼ 3387/621
Height (m)
Weight (kg)





Inhaled corticosteroids, n (%)
Oral corticosteroids, n (%)
Atopy, n (%)
Chronic sinusitis with polyps, n (%)
Asthma duration (years)
Table 1. Baseline characteristics. All results presented as mean  stanboth. After stratification by smoking status, non-
smoking subjects with asthma were seen to
have a positive association between DFEV1,ECRHS III (n ¼ 4257)
Non-asthma n ¼ 3606 Asthma n ¼ 651
1775 (49.2) 256 (39.3)
54.2 (7.1) 53.7 (7.1)
16.5 (16.2, 16.8) 21.1 (20.0, 22.3)
18.4 (17.9, 18.6) 23.9 (21.9, 26.1)
15.0 (14.6, 15.3) 19.6 (18.2, 21.0)
17.9 (17.6, 18.3) 23.4 (22.1, 24.8)
11.5 (11.0, 12.0) 11.9 (10.5, 13.4)
3.1 (0.73) 2.7 (0.74)
96.2 (13.6) 87.3 (16.4)
0.93 (0.45) 1.00 (0.67)
4.0 (0.94) 3.8 (0.93)
99.7 (13.0) 95.2 (13.7)
0.57 (0.4) 0.62 (0.5)
0.76 (0.06) 0.73 (0.08)
0.36 (0.27) 0.35 (0.35)
3.2 (0.73) 2.8 (0.73)
4.0 (0.94) 3.8 (0.93)
0.79 (0.06) 0.75 (0.08)
1.70 (0.10) 1.69 (0.10)
78.6 (16.4) 78.9 (16.5)
0.43 (0.46) 0.48 (0.47)
27.0 (4.7) 27.7 (5.5)
2955 (82.0) 554 (85.1)
651 (18.0) 97 (14.9)
24 (0.7) 128 (23.2)
7 (0.2) 5 (0.9)
675 (21.3) 168 (44.9)
34 (1.0) 18 (2.8)
28.4 (15.2)
dard deviation (SD) if nothing else is stated
DFEV1 DFVC DFEV1/FVC
mean (95% CI) p value mean (95% CI) p value mean (95% CI) p value
Non-asthma
ECHRS I / ECHRS III,
% change per year
0.93 (0.92, 0.95) 0.57 (0.56, 0.59) 0.34 (0.33, 0.34)
Smoking status
Non-smokers (n [ 2.943) 0.91 (0.89, 0.92) 0.57 (0.55, 0.59) 0.32 (0.31, 0.33)
Smokers (n [ 647) 1.05 (1.01, 1.08) <0.001 0.59 (0.56, 0.63) 0.22 0.42 (0.40, 0.44) <0.001
Sex
Men (n [ 1772) 0.89 (0.87, 0.91) 0.56 (0.54, 0.58) 0.30 (0.28, 0.31)
Women (n [ 1830) 0.98 (0.96, 1.00) <0.001 0.58 (0.56, 0.60) 0.19 0.37 (0.36, 0.39) <0.001
Asthma
ECHRS I / ECHRS III,
% change per year
1.00 (0.95, 1.05) 0.62 (0.58, 0.67) 0.35 (0.33, 0.38)
Smoking status
Non-smokers (n [ 553) 0.96 (0.67, 1.01) 0.60 (0.56, 0.65) 0.33 (0.30, 0.36)
Smokers (n [ 97) 1.26 (1.14, 1.38) <0.001 0.76 (0.64, 0.87) 0.009 0.47 (0.40, 0.55) <0.001
Sex
Men (n [ 256) 0.96 (0.88, 1.04) 0.61 (0.54, 0.68) 0.30 (0.26, 0.34)
Women (n [ 394) 1.03 (0.96, 1.09) 0.21 0.63 (0.58, 0.69) 0.61 0.39 (0.35, 0.42) 0.005
Table 2. Arithmetic means of lung function response (ECHRS I / ECHRS III, % change per year). Abbreviations: ECRHS I ¼ first survey of European Community Respiratory Health Survey, ECRHS














logFeNO DFEV1 DFVC DFEV1/FVC
ECRHS I / ECRHS III,
% change per year b-coefficient (95% CI) p value b-coefficient (95% CI) p value b-coefficient (95% CI) p value
Non-asthma
ECRHS I / ECRHS III,
% change per year
(All, n [ 3127)
0.003 (0.02, 0.02) 0.76 0.0009 (0.02, 0.02) 0.93 0.0009 (0.03, 0.03) 0.96
Smoking status
Non-smokers (n ¼ 2571) 0.01 (0.007, 0.03) 0.18 0.001 (0.02, 0.02) 0.91 0.02 (0.01, 0.05) 0.27
Smokers (n [ 556) 0.05 (0.09, 0.004) 0.07 0.02 (0.07, 0.04) 0.57 0.05 (0.12, 0.02) 0.18
Sex
Men (n ¼ 1555) 0.0001 (0.03, 0.03) 0.99 0.002 (0.03, 0.03) 0.88 0.006 (0.05, 0.05) 0.98
Women (n ¼ 1572) 0.005 (0.02, 0.03) 0.73 0.005 (0.03, 0.02) 0.74 0.0001 (0.04, 0.04) 0.99
Asthma
ECRHS I-ECRHS III,
% change per year
(All, n [ 315)
0.13 (0.07, 0.18) <0.001 0.07 (0.004, 0.14) 0.06 0.23 (0.12, 0.35) <0.001
Smoking status
Non-smokers (n [ 263) 0.16 (0.10, 0.23) <0.001 0.10 (0.01, 0.19) 0.02 0.26 (0.13, 0.38) <0.001
Smokers (n [ 52) 0.0007 (0.18, 0.18) 0.99 0.02 (0.21, 0.17) 0.80 0.07 (0.29, 0.44) 0.68
Sex
Men (n [ 113) 0.13 (0.004, 0.27) 0.06 0.07 (0.08, 0.21) 0.37 0.22 (0.01, 0.45) 0.06
Women (n [ 202) 0.15 (0.08, 0.22) <0.001 0.10 (0.008, 0.20) 0.03 0.24 (0.10, 0.38) 0.001
Table 3. Multiple linear regression, lung function decline (% changes per year) and the association with FeNO in in non-asthma/asthma subjects stratified by smoking status and sex,
respectively. Abbreviations: FeNO ¼ fractional exhaled NO nitric oxide, FEV1 ¼ forced expiratory volume in 1 s, FVC ¼ forced vital capacity, CI ¼ confidence interval, ECRHS I ¼ first survey of European
Community Respiratory Health Survey, ECRHS III ¼ third survey of European Community Respiratory Health Survey. Adjusted for sex, age, height, atopy, chronic sinusitis with polyps, asthma duration, inhaled



















Volume 14, No. 5, May 2021 9DFVC, and DFEV1/FVC ratio and higher FeNO
levels, p < 0.001, p ¼ 0.02, p < 0.001. Further,
after stratification by sex, asthmatic women
showed a positive association between DFEV1,
DFVC and DFEV1/FVC ratio and FeNO levels,
p < 0.001, p ¼ 0.03, p ¼ 0.001. No association
was seen in non-asthmatics, see Table 3.
Results were consistent after further
adjustment of BMI change over 20 years of
time. When oral steroids were added to the
list of covariates, the results showed similar b
coefficients and p values (data not shown). No
interaction was seen between sex and yearly
changes in lung function (FEV1, FVC, and
FEV1/FVC) after adjustment for age, height,
atopy, inhaled steroids, and study centre (data
not shown).FeNO and bronchodilator response
Asthmatic subjects had higher BD response with
regards to FEV1 and FVC compared with non-




(95% CI) p value
Non-Asthma
n [ 3440




2.3 (2.2, 2.5) 
Smokers n [ 622 2.6 (2.2, 2.9) 0.27 
Sex
Men (n [ 1688) 2.3 (2.1, 2.5) 
Women (n [ 1752) 2.5 (2.3, 2.7) 0.14 





Smokers n [ 93 5.5 (4.0, 7.0) 0.42
Sex
Men n ¼ 249 4.9 (4.1, 5.8) 
Women n ¼ 384 5.0 (4.2, 5.7) 0.97
Table 4. Arithmetic means of lung function response to BD (expressed
smoking status and sex, respectively. Abbreviations: BD ¼ bronchodilator,In non-asthmatic subjects, a positive association
was seen between higher % changes in FEV1 and
FeNO levels after BD use, after adjusting for sex,
age, height, weight, atopy, inhaled steroids,
smoking status, and study centre, p ¼ 0.02. No
association was seen between lung function
response to BD and FeNO levels in asthmatic
subjects, see Table 5.
After stratification by smoking status, non-
smoking subjects showed a positive association
between higher % change in FEV1 and FeNO
levels after BD use, whether they were non-
asthmatic, p ¼ 0.007, or asthmatic, p ¼ 0.03.
Further, when stratified by sex, women showed a
positive association between higher % changes in
FEV1 and FeNO levels after BD use, whether they
were non-asthmatic, p ¼ 0.007, or asthmatic,
p ¼ 0.04, Table 5. We also added oral steroids to
our covariates; the results showed the same
pattern (data not shown), except in asthmatic
women where the b coefficient (95% CI) was
0.007 (0.003, 0.02), p ¼ 0.16. No interactionsFVC, mean





0.9 (1.0, 0.7) 3.3 (3.2, 3.4)
1.0 (1.1, 0.8) 3.4 (3.2, 3.5)
0.4 (0.7, 0.3) 0.002 3.1 (2.8, 3.4) 0.06
0.6 (0.8, 0.4) 2.9 (2.7, 3.1)
1.2 (1.4, 0.9) <0.001 3.7 (3.5, 3.9) <0.001
.2 (0.8, 1.7) 3.7 (3.3, 4.1)
1.0 (0.6, 1.5) 3.8 (3.4, 4.2)
2.4 (1.2, 3.6) 0.03 3.0 (2.1, 4.0) 0.15
1.8 (1.1, 2.4) 3.0 (2.5, 3.6)
0.9 (0.3, 1.5) 0.08 4.1 (3.6, 4.6) 0.009
as pre/post change) in non-asthma/asthma subjects stratified by
FEV1 ¼ forced expiratory volume in 1 s, FVC ¼ forced vital capacity
logFeNO
Lung function response to BD %
change FEV1
Lung function response to BD %
change FVC
Lung function response to BD %
change FEV1/FVC
b-coefficient (95% CI) p value b-coefficient (95% CI) p value b-coefficient (95% CI) p value
Non-asthma (n [ 2993) 0.002 (0.0003, 0.004) 0.02 0.001 (0.0005, 0.003) 0.16 0.0007 (0.001, 0.003) 0.49
Smoking status
Non-smokers (n [ 2460) 0.003 (0.0007, 0.004) 0.007 0.001 (0.0008, 0.003) 0.26 0.001 (0.0008, 0.004) 0.20
Smokers (n [ 533) 0.00008 (0.004, 0.004) 0.97 0.003 (0.002, 0.007) 0.25 0.003 (0.008, 0.002) 0.29
Sex
Men (n [ 1486) 0.0008 (0.002, 0.003) 0.54 0.001 (0.001, 0.004) 0.30 0.0009 (0.004, 0.002) 0.57
Women (n [ 1507) 0.003 (0.0009, 0.006) 0.007 0.001 (0.001, 0.003) 0.38 0.002 (0.0003, 0.005) 0.08
Asthma (n [ 305) 0.005 (0.001, 0.011) 0.11 0.005 (0.001, 0.012 0.11 0.002 (0.007, 0.010) 0.69
Smoking status
Non-smokers (n [ 250) 0.008 (0.001, 0.015) 0.03 0.009 (0.001, 0.016) 0.02 0.002 (0.008, 0.011) 0.73
Smokers (n [ 50) 0.004 (0.007 0.016) 0.46 0.0006 (0.015, 0.014) 0.93 0.032 (0.003, 0.06) 0.03
Sex
Men (n [ 110) 0.002 (0.012, 0.008) 067 0.006 (0.006, 0.018) 0.35 0.014 (0.030, 0.003) 0.10
Women (n [ 195) 0.008 (0.0006, 0.015) 0.04 0.006 (0.002, 0.014) 0.14 0.007 (0.003, 0.017) 0.20
Table 5. Multiple linear regression analyses, lung function response to BD (expressed as % change) to FeNO in non-asthma/asthma subjects (adjusted) stratified by smoking status and
sex, respectively. Abbreviations: FeNO ¼ fractional exhaled NO nitric oxide, BD ¼ bronchodilator, FEV1 ¼ forced expiratory volume in 1 s, FVC ¼ forced vital capacity, CI ¼ confidence interval. Adjusted for sex,



















Volume 14, No. 5, May 2021 11were seen between sex and BD response (FEV1,
FVC, and FEV1/FVC) after adjustment for age,
height, atopy, inhaled steroids, and study centre
(data not shown).DISCUSSION
The main finding of the present study was that
a larger previous lung function decline over 20
years was associated with higher FeNO levels in
asthmatics in ECRHS III. We also found that a
higher BD response was associated with higher
FeNO levels in non-asthmatic subjects. After
subjects were stratified by sex and smoking sta-
tus, the association appeared to be stronger for
women and non-smokers, respectively, regardless
of asthma status.FeNO and lung function decline over time
Eosinophil inflammation, assessed through
blood cell counts, has been associated with faster
decline of FEV1/FVC ratios and FEV1 in a
population-based cohort of young adults.13 Also,
Backman et al, using a similar design to that in
our study, reported an association between
accelerated previous decline in FEV1 and blood
eosinophils among adults with asthma.32 This is
in line with our study, where we found that a
faster decline in lung function was associated
with higher FeNO levels in asthmatics.
Asthma is frequently characterised by eosino-
phil inflammation, mainly due to type-2 inflamma-
tion, and FeNO levels are associated with degree
of eosinophil airway inflammation.33 The
association between FeNO and change in lung
function has only been studied in selected
asthma populations.14–16 In a prospective study
by Matsunaga et al16 on non-smoking patients
with controlled asthma (n ¼ 140), subjects who
had persistently high levels of FeNO had an
accelerated decline in FEV1 and reduction in
bronchodilator response over time. Similar results
were shown by Van Veen et al,14 who
demonstrated that FeNO level was associated
with an excessive loss of lung function in non-
smoking, difficult-to-treat asthmatics.
After stratification by smoking and sex, a posi-
tive association was seen only in non-smokers and
women, respectively. The rationale for the firststratification was that current smokers have signif-
icantly lower FeNO levels,34,35 but faster lung
function decline7 than non-smokers. Current
smoking is a known determinant of FeNO levels in
both healthy subjects34,35 and asthmatics.36
Similarly, current smoking is related to faster lung
function decline both in non-asthmatic and asth-
matic individuals.37 Therefore, current smoking is
expected to relate both to lower FeNO and
higher lung function decline. Moreover, as higher
degree of smoking relates to further decreased
FeNO38 and larger lung function decrease,37 this
might explain the fact that the type-2-
inflammatory signal reflected by FeNO might be
impaired especially when looking at associations
with lung function decline in current smokers.
With regards to sex stratification, a rationale is
offered by a study by James et al demonstrating
that smoking subjects with asthma had a more
accelerated decline in lung function compared
with non-smokers, and this decline in lung function
was even greater in males with asthma.37 The
mechanisms behind these sex differences are not
fully understood, but appear to be related to
differences in genetics and hormones, as well as
sociocultural and environmental differences.39Bronchodilator response
Larger BD response was associated with higher
FeNO levels in non-asthmatic subjects. This has not
previously been studied in large populations of
healthy individuals. In previous analyses, which
included the populations studied herein and two
other populations, we found that FeNO levels were
related to the response to BD testing in asthmatics
as well.19 In the present analysis, this was found
only in non-smoking asthmatics. This may be
related to power, as the previous analysis was
based on a larger number of asthmatics. Other
studies have also found an association between
FeNO and the BD response in asthmatics.40 The
fact that we found an association only in non-
smoking asthmatics is probably related to the
fact that smoking reduces FeNO levels;35 thus, the
relation to BD response is impaired. The clinical
role of FeNO in smokers with asthma is still
debated.41
Somewhat surprisingly, we found a sex differ-
ence between FeNO and BD response, where
12 Nerpin et al. World Allergy Organization Journal (2021) 14:100544
http://doi.org/10.1016/j.waojou.2021.100544women appeared to have a stronger response. Sex
hormones has been shown to play an important
role in the development and progression of
asthma. In adults, experimental evidence from
human cells and animal studies have shown that
Th2-mediated airway inflammation is increased by
oestrogen and that testosterone has anti-
inflammatory effects.42
Previous studies have also indicated that
middle-aged women are at greater risk of asthma
than men.43,44 Possible mechanisms include
smaller airways,45 faster lung function decline
around menopause,46 sex differences in smoke
metabolism,47 and immunological48 or hormonal
differences.49Strengths and limitations
The main strength of the current study is that
ECRHS is a large, multicentre, population-based
cohort, which enabled us to conduct stratified an-
alyses. It has a standardised protocol with vali-
dated questionnaires and careful attention has
been paid to the quality and standardisation of
lung function and exhaled NO measurements.
Further, the study subjects came from different
geographical areas, indicating that these findings
could be valid in the general population.
Some limitations are worth mentioning. FeNO
was measured only in ECRHS III, we do not have
FeNO measurements at baseline or during the
study period, which means that we cannot express
a causal relationship. The present population was
recruited from both a random sample and a
symptomatic sample of responders in ECRHS. The
long follow-up time and the fact that ECRHS III was
the second follow-up should be taken into ac-
count. A response rate of just above 50% was
found for ECRHS participants in all three surveys.50
Therefore, selection bias cannot be ruled out,
although it is unlikely to have affected the
associations found in this study.CONCLUSIONS
Our study shows that participants with asthma
and faster lung function decline are characterised
by higher levels of FeNO at follow-up. It could be
speculated that achieving control of type-2
inflammation might result in slower lung functiondecline, but this must be tested in prospective
studies. Higher FeNO levels are associated with a
larger degree of response to bronchodilators.
Further studies are needed to evaluate the clinical
implications of our findings and to understand the
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